Role of Cardiac Steatosis and Lipotoxicity in Obesity Cardiomyopathy

Yingmei Zhang,Jun Ren

DOI: https://doi.org/10.1161/hypertensionaha.110.164178

IF: 9.8968

2011-01-01

Hypertension

Abstract:HomeHypertensionVol. 57, No. 2Role of Cardiac Steatosis and Lipotoxicity in Obesity Cardiomyopathy Free AccessArticle CommentaryPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessArticle CommentaryPDF/EPUBRole of Cardiac Steatosis and Lipotoxicity in Obesity Cardiomyopathy Yingmei Zhang and Jun Ren Yingmei ZhangYingmei Zhang From the Department of Cardiology (Y.Z.), Xijing Hospital, Fourth Military Medical University, Xi'an, China; and Center for Cardiovascular Research and Alternative Medicine (Y.Z., J.R.), University of Wyoming, Laramie, WY. and Jun RenJun Ren From the Department of Cardiology (Y.Z.), Xijing Hospital, Fourth Military Medical University, Xi'an, China; and Center for Cardiovascular Research and Alternative Medicine (Y.Z., J.R.), University of Wyoming, Laramie, WY. Originally published10 Jan 2011https://doi.org/10.1161/HYPERTENSIONAHA.110.164178Hypertension. 2011;57:148–150Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: January 1, 2011: Previous Version 1 See related article, pp 216–222The pandemic of obesity is a devastating health problem and contributes to premature morbidity and mortality. Results from clinical and experimental studies have identified a variety of unfavorable consequences of obesity including cardiovascular diseases, pulmonary diseases, cancer, and sleep disorders. An obesity-triggered parallel increase in the prevalence of type 2 diabetes mellitus is also expected to add to the overall cardiovascular burden of obesity. Components of metabolic syndrome such as dyslipidemia, hyperglycemia, insulin resistance, and hypertension are thought to play pivotal roles in obesity-associated sequelae responsible for atherosclerosis, cardiac hypertrophy, and ventricular dysfunction. The presence of 1 or more of these metabolic syndrome components can adversely affect multiple metabolic pathways resulting in alterations in glucose and lipid metabolism, fatty acid (FA) transport/storage/oxidation, oxygen consumption, redox status, and high-energy phosphate metabolism. Although the precise mechanism(s) of action responsible for metabolic derangement-induced cardiac abnormalities in obesity remains poorly understood, 1 theory that has received increasing attention focuses on lipid transport and storage, excessive FA oxidation (FAO), and lipotoxic injury to the heart.1,2 When energy intake exceeds expenditure, fat is stored as triacylglycerol (TG) in adipose tissue. In turn, once fat levels exceed the storage capacity of adipocytes, a variety of neutral lipids are released and accumulated in other cells and tissues including the heart. The presence of lipid inclusions within cardiomyocytes, a condition referred to as cardiac steatosis, has been confirmed in obesity and diabetes.3,4 Although recent evidence indicates that cardiac steatosis, increased availability of FA and excess FAO contribute to cardiac anomalies associated with obesity and type 2 diabetes, it has also been suggested that cardiac steatosis may be a compensatory mechanism used to neutralize FAs and their metabolites through esterification to neutral lipids.Generation of ATP for normal cardiac contractile function depends on a fine balance in the use of FA and carbohydrate as substrates. However, onset and development of obesity and type 2 diabetes result in an increased availability of FA, a concomitant overreliance on FA as an energy source, and accelerated FAO. In consequence, cardiomyocyte FA uptake often exceeds mitochondrial oxidative capacity, and cardiac steatosis ensues, leading to a build-up of lipotoxic intermediates such as ceramide and acylcarnitine. Collectively these events favor oxidative stress and apoptosis, and, mitochondria become damaged further compromising ATP production and cardiac contractile function. FA uptake exceeding FAO results in increased FA storage as TG and the accompanied cardiac contractile dysfunction. Myocardial TG accumulation may either protect the heart by "storing away" the detrimental lipid intermediates (eg, diacylglycerol, long-chain fatty acyl-CoA esters, and ceramide), or elicit severe lipotoxicity thereby compromising cardiac function.2 Meanwhile, the insulin-resistant heart in obesity and type 2 diabetes is unable to fully use glucose, forcing the heart to rely on FA for energy demand and thus prompting a vicious cycle of increased cardiomyocyte FA uptake, oxidation, and TG accumulation, all of which are hallmarks of lipotoxic cardiomyopathy. Whereas the pathophysiology of lipid accumulation on cardiac function has been defined, the clinical value of cardiac steatosis remains elusive in obesity and type 2 diabetes. Impaired glucose tolerance is accompanied by cardiac steatosis in humans and precedes the onset of type 2 diabetes and systolic dysfunction.5 Evidence from genetically modified mice with overexpression or targeted gene deletion of FA uptake protein (eg, cardiac-specific lipoprotein lipase [LpL],6 acyl-CoA synthetase,7 and FA transport protein [FATP]18) or that prevent lipid turnover (deletion of adipose triglyceride lipase gene [ATGL]) has revealed cardiomyocyte lipid deposition associated with cardiac dysfunction (Figure). For example, hearts from mice overexpressing LpL, the principal enzyme that hydrolyzes circulating TG and liberates free FAs to be used as energy, were dilated and exhibited systolic dysfunction. Increased free FA uptake with FATP1 overexpression contributes to early cardiomyocyte FA accumulation and subsequently increased cardiac FA metabolism. In this model, perturbation of cardiomyocyte lipid homeostasis leads to cardiac dysfunction with pathophysiological findings reminiscent of those seen in diabetes in the absence of systemic metabolic disturbances.8 These findings support the concept that cardiac-restricted steatosis may directly prompt cardiac anomalies independent of systemic obesity. In addition, overexpression of peroxisome proliferator-activated receptor (PPAR)α and PPARγ using the α-myosin heavy chain (MHC) promoter led to overt cardiac lipid accumulation and cardiomyopathy.9,10 The pathophysiology behind cardiomyopathy with PPARα and PPARγ overexpression is unclear but has been speculated to be associated with excess FAO and/or cardiac steatosis.9,10 In a recent study from the Kelly laboratory, cardiac function in cardiac-specific MHC-PPARα mice bred into a CD36 or LpL-deficient background (PPARα/hsLpLko and PPARα/CD36ko models) was evaluated.9 Preserved cardiac function was found in these mice against PPARα overexpression in association with the improved mitochondrial ultrastructure and reactivation of transcriptional regulators of mitochondrial function.9 Deficiency of CD36, a sarcolemmal protein required for FA uptake into cardiomyocytes, reduced uptake of free and lipoprotein-derived FA. This finding is consistent with the notion that overtly increased expression of CD36 is present in diabetes, insulin resistance and cardiac steatosis.2Download figureDownload PowerPointFigure. Evidence from genetically manipulated murine models of FA transporting protein depicts attribution of lipid accumulation (cardiac steatosis) to cardiac remodeling, mitochondrial damage and cardiac dysfunction. ACS indicates acyl-CoA synthetase; ATGL, adipose triglyceride lipase gene; FATP1, fatty acid transport protein 1; DAGT, diacylglycerol acyl transferase; LpL, lipoprotein lipase.In this issue of Hypertension, Glenn et al created a new transgenic model of cardiac lipid accumulation using forced expression of diacylglycerol acyl transferase (DGAT)1 in cardiomyocytes.11 Over time, the DGAT1 transgenic mice exhibited increased cardiomyocyte lipid accumulation, cardiac fibrosis, ventricular remodeling, and cardiac contractile dysfunction and decreased mitochondrial biogenesis in the absence of obesity, insulin resistance or systemic dyslipidemia. These findings favor the notion that isolated cardiac steatosis compromises cardiac function independent of effects accrued from generalized adiposity or dyslipidemia. Their findings support the concept that cardiac-restricted steatosis may be directly responsible for cardiac anomalies in obesity independent of systemic metabolic derangements. Accordingly, focusing on cardiac steatosis as a potential therapeutic target in the management of lipotoxic cardiomyopathy in obesity and type 2 diabetes may have merit. DGAT is a microsomal enzyme expressed in mammalian tissues that catalyzes the esterification of 1,2-diacylglycerol with fatty acyl CoA to form TG. In contrast to their findings, an earlier study using the same model demonstrated that DGAT1 expression increases heart TG content but rather ameliorates lipotoxicity.12 As Glenn et al rightfully pointed out, this apparent paradox in the disparate DGAT1 overexpression-induced cardiac responses is time-dependent. DGAT1-dependent TG synthesis can be cardioprotective in acute or subacute FA-overload situations, but over time, accrual of TG leads to lipotoxicity. Interestingly, a recent report from the Goldberg group suggested that PPARα deficiency mitigates PPARγ-induced cardiolipotoxicity including dilated cardiomyopathy, endoplasmic reticulum stress, and apoptosis despite increased FA uptake gene expression, FAO, and increased lipotoxic ceramide levels. The preserved cardiac function in the PPARα-deficiency/PPARγ-crossed mice was accompanied by larger lipid droplet size and decreased levels of the toxic intermediate acylcarnitine. More surprisingly, mRNA expression was increased for genes governing lipid uptake, transport, and storage including Cd36, Atgl, and Dgat in PPARα-deficiency/PPARγ mice with lessened cardiac dysfunction, oxidative stress, and apoptosis. These findings seem to contradict a role of cardiac steatosis in the pathogenesis of lipotoxic cardiomyopathy. However, these authors argued that partitioning of lipid into storage and oxidation (redistribution) can reverse cardiolipotoxicity despite increased levels of diacylglycerol and ceramide, thus suggesting a mechanism for shunting FAs into lipid droplets and then allowing TG hydrolysis into oxidative substrates.10 Given the apparent controversies between cardiac steatosis and cardiac function, the jury is still out with regard to the precise role of cardiac steatosis (in particular, macro- versus microsteatosis) in lipotoxic cardiomyopathy in obesity. Last but not least, several of the seminal studies involving genetic modification of lipid uptake or turnover proteins used the Cre-loxP system to study the physiological effects of gene knockout. However, an observation from the Hall laboratory found that cardiac-specific Cre-recombinase may trigger a transient reduction in cardiac systolic function,13 although such transient reduction in cardiac function may not have a long-term impact on cardiac function. Nonetheless, caution should be taken in lipotoxic cardiomyopathy derived from the Cre-loxP–based genetic models.Because of the potential involvement of DGAT1 in disorders associated with TG metabolism and pathogenesis of a variety of diseases including obesity, insulin resistance, type 2 diabetes, and dyslipidemia, this molecule has received attention as a potential new target for the treatment of obesity. The pharmacological profile of a series of small molecule DGAT1 inhibitors such as RO-6036 is becoming available with several DGAT1-selective inhibitors in preclinical research. Observation based on DGAT1 genetic deletion and inhibition has confirmed that the reduced DGAT1 activity leads to improved insulin sensitivity, lowered plasma glucose, loss in either body weight or body weight gain, improved plasma lipid profiles (eg, nonesterified FAs, TG, and cholesterol), reduced hepatic steatosis, and altered secretion of gastrointestinal peptides.14 Moreover, a number of DGAT1 inhibitors, such as BAY-74-4113, PF-04620110, and LCQ-908 from Bayer, have entered clinical trials. Thus, a new spectrum of DGAT1 inhibitors may be used to reconcile cardiac steatosis–induced cardiac remodeling and contractile dysfunction in obesity and other cardiovascular diseases.Sources of FundingNone.DisclosuresNone.FootnotesThe opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.Correspondence to Jun Ren, Center for Cardiovascular Research and Alternative Medicine University of Wyoming College of Health Sciences, Laramie, WY 82071. E-mail [email protected]eduReferences1. Lopaschuk GD, Folmes CD, Stanley WC. Cardiac energy metabolism in obesity. Circ Res. 2007; 101:335–347.LinkGoogle Scholar2. Brindley DN, Kok BP, Kienesberger PC, Lehner R, Dyck JR. Shedding light on the enigma of myocardial lipotoxicity: the involvement of known and putative regulators of fatty acid storage and mobilization. Am J Physiol Endocrinol Metab. 2010; 298:E897–E908.CrossrefMedlineGoogle Scholar3. Buchanan J, Mazumder PK, Hu P, Chakrabarti G, Roberts MW, Yun UJ, Cooksey RC, Litwin SE, Abel ED. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology. 2005; 146:5341–5349.CrossrefMedlineGoogle Scholar4. Christoffersen C, Bollano E, Lindegaard ML, Bartels ED, Goetze JP, Andersen CB, Nielsen LB. Cardiac lipid accumulation associated with diastolic dysfunction in obese mice. Endocrinology. 2003; 144:3483–3490.CrossrefMedlineGoogle Scholar5. McGavock JM, Lingvay I, Zib I, Tillery T, Salas N, Unger R, Levine BD, Raskin P, Victor RG, Szczepaniak LS. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation. 2007; 116:1170–1175.LinkGoogle Scholar6. Yagyu H, Chen G, Yokoyama M, Hirata K, Augustus A, Kako Y, Seo T, Hu Y, Lutz EP, Merkel M, Bensadoun A, Homma S, Goldberg IJ. Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest. 2003; 111:419–426.CrossrefMedlineGoogle Scholar7. Chiu HC, Kovacs A, Ford DA, Hsu FF, Garcia R, Herrero P, Saffitz JE, Schaffer JE. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest. 2001; 107:813–822.CrossrefMedlineGoogle Scholar8. Chiu HC, Kovacs A, Blanton RM, Han X, Courtois M, Weinheimer CJ, Yamada KA, Brunet S, Xu H, Nerbonne JM, Welch MJ, Fettig NM, Sharp TL, Sambandam N, Olson KM, Ory DS, Schaffer JE. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res. 2005; 96:225–233.LinkGoogle Scholar9. Duncan JG, Bharadwaj KG, Fong JL, Mitra R, Sambandam N, Courtois MR, Lavine KJ, Goldberg IJ, Kelly DP. Rescue of cardiomyopathy in peroxisome proliferator-activated receptor-alpha transgenic mice by deletion of lipoprotein lipase identifies sources of cardiac lipids and peroxisome proliferator-activated receptor-alpha activators. Circulation. 2010; 121:426–435.LinkGoogle Scholar10. Son NH, Yu S, Tuinei J, Arai K, Hamai H, Homma S, Shulman GI, Abel ED, Goldberg IJ. PPARgamma-induced cardiolipotoxicity in mice is ameliorated by PPARalpha deficiency despite increases in fatty acid oxidation. J Clin Invest. 2010; 120:3443–3454.CrossrefMedlineGoogle Scholar11. Glenn DJ, Wang F, Nishimoto M, Cruz MC, Uchida Y, Holleran WM, Zhang Y, Yeghiazarians Y, Gardner DG. A murine model of isolated cardiac steatosis leads to cardiomyopathy. Hypertension. 2011; 57:216–222.LinkGoogle Scholar12. Liu L, Shi X, Bharadwaj KG, Ikeda S, Yamashita H, Yagyu H, Schaffer JE, Yu YH, Goldberg IJ. Dgat1 expression increases heart triglyceride content but ameliorates lipotoxicity. J Biol Chem. 2009; 284:36312–36323.CrossrefMedlineGoogle Scholar13. Smith GH, Hall ME, Stec DE, Hall JE. Cardiac-specific Cre-recombinase causes a dose-dependent transient reduction in systolic function. FASEB J. 2010; 24:596.3. Abstract.CrossrefGoogle Scholar14. Birch AM, Buckett LK, Turnbull AV. Dgat1 inhibitors as anti-obesity and anti-diabetic agents. Curr Opin Drug Discov Devel. 2010; 13:489–496.MedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Wang S, Liu B, Zhang F, Li Y, Su X, Yang C, Cong B and Zhang Z (2023) Abnormal fatty acid metabolism and ceramide expression may discriminate myocardial infarction from strangulation death: A pilot study, Tissue and Cell, 10.1016/j.tice.2022.101984, 80, (101984), Online publication date: 1-Feb-2023. Liu X, Liu L, Zhao J, Wang H and Li Y (2022) Mechanotransduction regulates inflammation responses of epicardial adipocytes in cardiovascular diseases, Frontiers in Endocrinology, 10.3389/fendo.2022.1080383, 13 Xu Z, Qin Y, Lv B, Tian Z and Zhang B (2022) Intermittent Fasting Improves High-Fat Diet-Induced Obesity Cardiomyopathy via Alleviating Lipid Deposition and Apoptosis and Decreasing m6A Methylation in the Heart, Nutrients, 10.3390/nu14020251, 14:2, (251) Forte M, Rodolico D, Ameri P, Catalucci D, Chimenti C, Crotti L, Schirone L, Pingitore A, Torella D, Iacovone G, Valenti V, Schiattarella G, Perrino C and Sciarretta S (2022) Molecular mechanisms underlying the beneficial effects of exercise and dietary interventions in the prevention of cardiometabolic diseases, Journal of Cardiovascular Medicine, 10.2459/JCM.0000000000001397, Publish Ahead of Print Ren J, Wu N, Wang S, Sowers J and Zhang Y (2021) Obesity cardiomyopathy: evidence, mechanisms, and therapeutic implications, Physiological Reviews, 10.1152/physrev.00030.2020, 101:4, (1745-1807), Online publication date: 1-Oct-2021. Kaneko H, Itoh H, Kiriyama H, Kamon T, Fujiu K, Morita K, Michihata N, Jo T, Takeda N, Morita H, Yasunaga H and Komuro I (2021) Lipid Profile and Subsequent Cardiovascular Disease among Young Adults Aged < 50 Years, The American Journal of Cardiology, 10.1016/j.amjcard.2020.11.038, 142, (59-65), Online publication date: 1-Mar-2021. Trivedi P, Bartlett J, Mercer A, Slade L, Surette M, Ballabio A, Flibotte S, Hussein B, Rodrigues B, Kienesberger P and Pulinilkunnil T (2020) Loss of function of transcription factor EB remodels lipid metabolism and cell death pathways in the cardiomyocyte, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 10.1016/j.bbadis.2020.165832, 1866:10, (165832), Online publication date: 1-Oct-2020. Álvarez-Aliaga A, Frómeta-Guerra A, Suárez-Quesada A, del Llano-Sosa D, Berdú-Saumell J and Lago-Santiesteban Y (2020) Prognostic model of the adaptive changes from hypertensive cardiopathy: from mild diastolic dysfunction to depressed systolic function, Medwave, 10.5867/medwave.2020.03.7873, 20:03, (e7873-e7873) Tsai S, Ghazizadeh Z, Wang H, Amin S, Ortega F, Badieyan Z, Hsu Z, Gordillo M, Kumar R, Christini D, Evans T and Chen S (2019) A human embryonic stem cell reporter line for monitoring chemical-induced cardiotoxicity, Cardiovascular Research, 10.1093/cvr/cvz148, 116:3, (658-670), Online publication date: 1-Mar-2020. Pérez‐Ramírez I, González‐Dávalos M, Mora O, Silva I, Gallegos‐Corona M, Guzmán‐Maldonado S and Reynoso‐Camacho R (2019) Cardiac Lipid Metabolism Is Modulated by Casimiroa edulis and Crataegus pubescens Aqueous Extracts in High Fat and Fructose (HFF) Diet‐Fed Obese Rats , European Journal of Lipid Science and Technology, 10.1002/ejlt.201900157, 121:11, (1900157), Online publication date: 1-Nov-2019. He F, Zheng W, Chen Y, Mo C and Chen Y (2019) Development and validation of a simple and sensitive high‐resolution LC/MS method for determination of PF‐04620110 in dog plasma: Application to a pharmacokinetic study, Biomedical Chromatography, 10.1002/bmc.4562, 33:9, Online publication date: 1-Sep-2019. Chae Y, Song J, Ahn J, Bae M and Lee K (2018) Model-based pharmacokinetic and pharmacodynamic analysis for acute effects of a small molecule inhibitor of diacylglycerol acyltransferase-1 in the TallyHo/JngJ polygenic mouse, Xenobiotica, 10.1080/00498254.2018.1496303, 49:7, (823-832), Online publication date: 3-Jul-2019. Li L, Zhang X, Zhang Q, Jia J, Zhang J, Zhang D, Song H, Chen B, Hu J and Huang Y (2019) Myocardial Adipose Triglyceride Lipase Overexpression Protects against Burn-Induced Cardiac Lipid Accumulation and Injury, Oxidative Medicine and Cellular Longevity, 10.1155/2019/6428924, 2019, (1-16), Online publication date: 16-May-2019. AlGhuraibawi W, Stromp T, Holtkamp R, Lam B, Rehwald W, Leung S and Vandsburger M (2019) CEST MRI reveals a correlation between visceral fat mass and reduced myocardial creatine in obese individuals despite preserved ventricular structure and function, NMR in Biomedicine, 10.1002/nbm.4104, (e4104) Wang S, Wang C, Turdi S, Richmond K, Zhang Y and Ren J (2018) ALDH2 protects against high fat diet-induced obesity cardiomyopathy and defective autophagy: role of CaM kinase II, histone H3K9 methyltransferase SUV39H, Sirt1, and PGC-1α deacetylation, International Journal of Obesity, 10.1038/s41366-018-0030-4, 42:5, (1073-1087), Online publication date: 1-May-2018. Varbo A and Nordestgaard B (2017) Nonfasting Triglycerides, Low-Density Lipoprotein Cholesterol, and Heart Failure Risk, Arteriosclerosis, Thrombosis, and Vascular Biology, 38:2, (464-472), Online publication date: 1-Feb-2018. Ren J and Zhang Y (2018) Autophagy as a Therapeutic Target for Cardiovascular Complications in Obesity—Concepts, Controversies, and Challenges Autophagy and Cardiometabolic Diseases, 10.1016/B978-0-12-805253-2.00010-9, (117-126), . Engin A (2017) Eat and Death: Chronic Over-Eating Obesity and Lipotoxicity, 10.1007/978-3-319-48382-5_3, (53-80), . Zhao X, Shen C, Zhu H, Wang C, Liu X, Sun X, Han S, Wang P, Dong Z, Ma X, Hu K, Sun A and Ge J (2016) Trans-Fatty Acids Aggravate Obesity, Insulin Resistance and Hepatic Steatosis in C57BL/6 Mice, Possibly by Suppressing the IRS1 Dependent Pathway, Molecules, 10.3390/molecules21060705, 21:6, (705) Zhang Y and Ren J (2016) Epigenetics and obesity cardiomyopathy: From pathophysiology to prevention and management, Pharmacology & Therapeutics, 10.1016/j.pharmthera.2016.03.005, 161, (52-66), Online publication date: 1-May-2016. Cabalén M, Cabral M, Sanmarco L, Andrada M, Onofrio L, Ponce N, Aoki M, Gea S and Cano R (2016) Chronic Trypanosoma cruzi infection potentiates adipose tissue macrophage polarization toward an anti-inflammatory M2 phenotype and contributes to diabetes progression in a diet-induced obesity model , Oncotarget, 10.18632/oncotarget.7630, 7:12, (13400-13415), Online publication date: 22-Mar-2016. Treviño S, Velázquez-Vázquez D, Sánchez-Lara E, Diaz-Fonseca A, Flores-Hernandez J, Pérez-Benítez A, Brambila-Colombres E and González-Vergara E (2016) Metforminium Decavanadate as a Potential Metallopharmaceutical Drug for the Treatment of Diabetes Mellitus, Oxidative Medicine and Cellular Longevity, 10.1155/2016/6058705, 2016, (1-14), . Haggerty C, Mattingly A, Kramer S, Binkley C, Jing L, Suever J, Powell D, Charnigo R, Epstein F and Fornwalt B (2015) Left ventricular mechanical dysfunction in diet-induced obese mice is exacerbated during inotropic stress: a cine DENSE cardiovascular magnetic resonance study, Journal of Cardiovascular Magnetic Resonance, 10.1186/s12968-015-0180-7, 17:1, Online publication date: 1-Dec-2015. Cozzolino D, Grandone A, Cittadini A, Palmiero G, Esposito G, De Bellis A, Furlan R, Perrotta S, Perrone L, Torella D, Miraglia del Giudice E and Minamino T (2015) Subclinical Myocardial Dysfunction and Cardiac Autonomic Dysregulation Are Closely Associated in Obese Children and Adolescents: The Potential Role of Insulin Resistance, PLOS ONE, 10.1371/journal.pone.0123916, 10:4, (e0123916) Diop S, Bisharat-Kernizan J, Birse R, Oldham S, Ocorr K and Bodmer R (2015) PGC-1/Spargel Counteracts High-Fat-Diet-Induced Obesity and Cardiac Lipotoxicity Downstream of TOR and Brummer ATGL Lipase, Cell Reports, 10.1016/j.celrep.2015.02.022, 10:9, (1572-1584), Online publication date: 1-Mar-2015. Yu X, Yang G and Song W (2014) Based on Class D Amplifier Magnetic Resonance Wireless Transmission Technology, Applied Mechanics and Materials, 10.4028/www.scientific.net/AMM.721.591, 721, (591-594) Nakanishi T and Kato S (2014) Impact of diabetes mellitus on myocardial lipid deposition: An autopsy study, Pathology - Research and Practice, 10.1016/j.prp.2014.04.008, 210:12, (1018-1025), Online publication date: 1-Dec-2014. Chou I, Chiu Y, Ding S, Liu B, Lin Y and Chen C (2014) Adiponectin receptor 1 overexpression reduces lipid accumulation and hypertrophy in the heart of diet-induced obese mice – possible involvement of oxidative stress and autophagy, Endocrine Research, 10.3109/07435800.2013.879165, 39:4, (173-179), Online publication date: 1-Nov-2014. Bounhoure J, Galinier M, Roncalli J and Massabuau P (2014) Obésité et Pronostic de l'insuffisance cardiaque : le paradoxe de l'obésité, mythe ou réalité ?, Bulletin de l'Académie Nationale de Médecine, 10.1016/S0001-4079(19)31377-9, 198:1, (61-70), Online publication date: 1-Jan-2014. Kramer S, Powell D, Haggerty C, Binkley C, Mattingly A, Cassis L, Epstein F and Fornwalt B (2013) Obesity reduces left ventricular strains, torsion, and synchrony in mouse models: a cine displacement encoding with stimulated echoes (DENSE) cardiovascular magnetic resonance study, Journal of Cardiovascular Magnetic Resonance, 10.1186/1532-429X-15-109, 15:1, Online publication date: 1-Dec-2013. Mahmod M, Bull S, Suttie J, Pal N, Holloway C, Dass S, Myerson S, Schneider J, De Silva R, Petrou M, Sayeed R, Westaby S, Clelland C, Francis J, Ashrafian H, Karamitsos T and Neubauer S (2013) Myocardial Steatosis and Left Ventricular Contractile Dysfunction in Patients With Severe Aortic Stenosis, Circulation: Cardiovascular Imaging, 6:5, (808-816), Online publication date: 1-Sep-2013. Lee K, Choi S, Song J, Seo H, Chae Y, Cho H, Ahn J, Ahn S and Bae M (2013) Determination of PF-04620110, a novel inhibitor of diacylglycerol acyltransferase-1, in rat plasma using liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic studies, Biomedical Chromatography, 10.1002/bmc.2869, 27:7, (846-852), Online publication date: 1-Jul-2013. Maloney K and Schoppe C (2013) Obesity and Non-Atherosclerotic Cardiovascular Disease, Academic Forensic Pathology, 10.23907/2013.002, 3:1, (8-12), Online publication date: 1-Mar-2013. Turdi S, Ge W, Hu N, Bradley K, Wang X and Ren J (2013) Interaction between maternal and postnatal high fat diet leads to a greater risk of myocardial dysfunction in offspring via enhanced lipotoxicity, IRS-1 serine phosphorylation and mitochondrial defects, Journal of Molecular and Cellular Cardiology, 10.1016/j.yjmcc.2012.12.007, 55, (117-129), Online publication date: 1-Feb-2013. DeMarco V, Ford D, Henriksen E, Aroor A, Johnson M, Habibi J, Ma L, Yang M, Albert C, Lally J, Ford C, Prasannarong M, Hayden M, Whaley-Connell A and Sowers J (2013) Obesity-Related Alterations in Cardiac Lipid Profile and Nondipping Blood Pressure Pattern during Transition to Diastolic Dysfunction in Male db/db Mice, Endocrinology, 10.1210/en.2012-1835, 154:1, (159-171), Online publication date: 1-Jan-2013. Li Z, Woollard J, Ebrahimi B, Crane J, Jordan K, Lerman A, Wang S and Lerman L (2012) Transition From Obesity to Metabolic Syndrome Is Associated With Altered Myocardial Autophagy and Apoptosis, Arteriosclerosis, Thrombosis, and Vascular Biology, 32:5, (1132-1141), Online publication date: 1-May-2012.Zhang Y, Yuan M, Bradley K, Dong F, Anversa P and Ren J (2012) Insulin-Like Growth Factor 1 Alleviates High-Fat Diet–Induced Myocardial Contractile Dysfunction, Hypertension, 59:3, (680-693), Online publication date: 1-Mar-2012. Birse R and Bodmer R (2011) Lipotoxicity and cardiac dysfunction in mammals and Drosophila , Critical Reviews in Biochemistry and Molecular Biology, 10.3109/10409238.2011.599830, 46:5, (376-385), Online publication date: 1-Oct-2011. Pulakat L, DeMarco V, Ardhanari S, Chockalingam A, Gul R, Whaley-Connell A and Sowers J (2011) Adaptive mechanisms to compensate for overnutrition-induced cardiovascular abnormalities, American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 10.1152/ajpregu.00316.2011, 301:4, (R885-R895), Online publication date: 1-Oct-2011. Turdi S, Kandadi M, Zhao J, Huff A, Du M and Ren J (2011) Deficiency in AMP-activated protein kinase exaggerates high fat diet-induced cardiac hypertrophy and contractile dysfunction, Journal of Molecular and Cellular Cardiology, 10.1016/j.yjmcc.2010.12.007, 50:4, (712-722), Online publication date: 1-Apr-2011. February 2011Vol 57, Issue 2 Advertisement Article InformationMetrics © 2011 American Heart Association, Inc.https://doi.org/10.1161/HYPERTENSIONAHA.110.164178PMID: 21220703 Originally publishedJanuary 10, 2011 PDF download Advertisement SubjectsContractile FunctionHeart FailureMyocardial Biology